{"id":56882,"date":"2026-02-11T21:17:37","date_gmt":"2026-02-11T13:17:37","guid":{"rendered":"https:\/\/flcube.com\/?p=56882"},"modified":"2026-02-11T21:17:39","modified_gmt":"2026-02-11T13:17:39","slug":"pfizers-cresemba-wins-nmpa-pediatric-approval-for-invasive-fungal-infections","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56882","title":{"rendered":"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections"},"content":{"rendered":"\n

Pfizer Inc.<\/strong> (NYSE:\u202fPFE<\/a><\/strong>) announced that the National Medical Products Administration (NMPA)<\/strong> has approved an indication expansion<\/strong> for Cresemba (isavuconazole)<\/strong>, its broad-spectrum triazole antifungal<\/strong>, to include invasive aspergillosis (IA)<\/strong> and invasive mucormycosis (IM)<\/strong> in pediatric patients aged 6 to under 18 years<\/strong> (body weight \u226516\u202fkg). The approval extends Cresemba’s China market presence<\/strong> beyond the adult indication granted in December\u202f2021<\/strong>, addressing critical unmet needs in immunocompromised children<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Pfizer Inc. (NYSE:\u202fPFE)<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Asset<\/strong><\/td>Cresemba (isavuconazole) \u2013 Triazole antifungal<\/td><\/tr>
New Indication<\/strong><\/td>Invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients (6 to <18 years, \u226516\u202fkg)<\/td><\/tr>
Adult Approval<\/strong><\/td>China: December\u202f2021 (oral); December\u202f2022 (injection)<\/td><\/tr>
Global Origin<\/strong><\/td>Co-developed by Astellas<\/strong> and Basilea Pharmaceuticals<\/strong>; US approval 2015<\/td><\/tr>
Pfizer Rights<\/strong><\/td>Exclusive commercialization (China + 16 Asia-Pacific countries, ex-Japan) since July\u202f2017<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Profile & Pediatric Expansion<\/h2>\n\n\n\n
Feature<\/th>Cresemba Specification<\/th>Pediatric Strategic Value<\/th><\/tr><\/thead>
Spectrum<\/strong><\/td>Broad-spectrum triazole<\/strong> \u2013 Aspergillus, Mucorales, and other filamentous fungi<\/td>Addresses two most lethal invasive fungal infections<\/strong> in immunocompromised hosts<\/td><\/tr>
Formulation<\/strong><\/td>Oral capsules and intravenous injection<\/td>Flexible administration for hospitalized and ambulatory pediatric patients<\/td><\/tr>
Safety Profile<\/strong><\/td>Favorable vs. voriconazole<\/strong> (hepatotoxicity, neurotoxicity, QT prolongation)<\/td>Critical for pediatric populations with limited therapeutic windows<\/td><\/tr>
Weight-Based Dosing<\/strong><\/td>\u226516\u202fkg threshold aligns with pharmacokinetic modeling<\/td>Enables precise dosing in school-age children and adolescents<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Positioning<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
Pediatric Fungal Disease Burden<\/strong><\/td>Invasive aspergillosis<\/strong>: 5-15% mortality in pediatric hematology-oncology; mucormycosis<\/strong>: 50-80% mortality if untreated\u2014highest in diabetic ketoacidosis and immunocompromised<\/td><\/tr>
China Market Gap<\/strong><\/td>Limited pediatric antifungal options<\/strong>; voriconazole (Pfizer) and amphotericin B dominate but with significant toxicity limitations<\/td><\/tr>
Cresemba Differentiation<\/strong><\/td>First and only triazole<\/strong> with simultaneous IA and IM approval<\/strong> in pediatrics; oral bioavailability<\/strong> enables step-down therapy<\/td><\/tr>
Pfizer Anti-Infective Portfolio<\/strong><\/td>Cresemba complements Zavicefta (ceftazidime-avibactam)<\/strong> and Prevnar<\/strong> franchise; strengthens hospital-critical care presence<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercial Outlook<\/h2>\n\n\n\n
Priority<\/th>Execution Plan<\/th>Timeline<\/th><\/tr><\/thead>
Launch<\/strong><\/td>Pediatric hospital formulary access; hematology-oncology and ICU specialist education<\/td>Q1-Q2\u202f2026<\/td><\/tr>
Reimbursement<\/strong><\/td>NRDL pediatric indication expansion negotiation<\/td>2026-2027<\/td><\/tr>
Market Expansion<\/strong><\/td>Position as first-line empiric therapy<\/strong> in febrile neutropenia with suspected mold infection<\/td>Ongoing<\/td><\/tr>
Global Alignment<\/strong><\/td>Harmonize China pediatric data with FDA\/EMA pediatric investigation plans<\/td>2026-2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Cresemba pediatric commercial performance in China, NRDL reimbursement expansion, and competitive dynamics with generic voriconazole and novel antifungals (rezafungin, ibrexafungerp). Actual results may differ due to hospital procurement delays, antifungal stewardship restrictions, and pediatric clinical trial enrollment for additional age groups.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Pfizer Inc. (NYSE:\u202fPFE) announced that the National Medical Products Administration (NMPA) has approved an indication…<\/p>\n","protected":false},"author":1,"featured_media":56883,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[863,309,15],"class_list":["post-56882","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nyse-pfe","tag-pfizer","tag-product-approvals"],"yoast_head":"\nPfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE:\u202fPFE) announced that the National Medical Products Administration (NMPA) has approved an indication expansion for Cresemba (isavuconazole), its broad-spectrum triazole antifungal, to include invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients aged 6 to under 18 years (body weight \u226516\u202fkg). The approval extends Cresemba's China market presence beyond the adult indication granted in December\u202f2021, addressing critical unmet needs in immunocompromised children.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56882\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE:\u202fPFE) announced that the National Medical Products Administration (NMPA) has approved an indication expansion for Cresemba (isavuconazole), its broad-spectrum triazole antifungal, to include invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients aged 6 to under 18 years (body weight \u226516\u202fkg). The approval extends Cresemba's China market presence beyond the adult indication granted in December\u202f2021, addressing critical unmet needs in immunocompromised children.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56882\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-11T13:17:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-11T13:17:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56882#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56882\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections\",\"datePublished\":\"2026-02-11T13:17:37+00:00\",\"dateModified\":\"2026-02-11T13:17:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56882\"},\"wordCount\":404,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56882#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1102.webp\",\"keywords\":[\"NYSE: PFE\",\"Pfizer\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56882#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56882\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56882\",\"name\":\"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56882#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56882#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1102.webp\",\"datePublished\":\"2026-02-11T13:17:37+00:00\",\"dateModified\":\"2026-02-11T13:17:39+00:00\",\"description\":\"Pfizer Inc. (NYSE:\u202fPFE) announced that the National Medical Products Administration (NMPA) has approved an indication expansion for Cresemba (isavuconazole), its broad-spectrum triazole antifungal, to include invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients aged 6 to under 18 years (body weight \u226516\u202fkg). The approval extends Cresemba's China market presence beyond the adult indication granted in December\u202f2021, addressing critical unmet needs in immunocompromised children.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56882#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56882\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56882#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56882#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections - Insight, China's Pharmaceutical Industry","description":"Pfizer Inc. (NYSE:\u202fPFE) announced that the National Medical Products Administration (NMPA) has approved an indication expansion for Cresemba (isavuconazole), its broad-spectrum triazole antifungal, to include invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients aged 6 to under 18 years (body weight \u226516\u202fkg). The approval extends Cresemba's China market presence beyond the adult indication granted in December\u202f2021, addressing critical unmet needs in immunocompromised children.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56882","og_locale":"en_US","og_type":"article","og_title":"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections","og_description":"Pfizer Inc. (NYSE:\u202fPFE) announced that the National Medical Products Administration (NMPA) has approved an indication expansion for Cresemba (isavuconazole), its broad-spectrum triazole antifungal, to include invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients aged 6 to under 18 years (body weight \u226516\u202fkg). The approval extends Cresemba's China market presence beyond the adult indication granted in December\u202f2021, addressing critical unmet needs in immunocompromised children.","og_url":"https:\/\/flcube.com\/?p=56882","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-11T13:17:37+00:00","article_modified_time":"2026-02-11T13:17:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56882#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56882"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections","datePublished":"2026-02-11T13:17:37+00:00","dateModified":"2026-02-11T13:17:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56882"},"wordCount":404,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56882#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1102.webp","keywords":["NYSE: PFE","Pfizer","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56882#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56882","url":"https:\/\/flcube.com\/?p=56882","name":"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56882#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56882#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1102.webp","datePublished":"2026-02-11T13:17:37+00:00","dateModified":"2026-02-11T13:17:39+00:00","description":"Pfizer Inc. (NYSE:\u202fPFE) announced that the National Medical Products Administration (NMPA) has approved an indication expansion for Cresemba (isavuconazole), its broad-spectrum triazole antifungal, to include invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients aged 6 to under 18 years (body weight \u226516\u202fkg). The approval extends Cresemba's China market presence beyond the adult indication granted in December\u202f2021, addressing critical unmet needs in immunocompromised children.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56882#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56882"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56882#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1102.webp","width":1080,"height":608,"caption":"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56882#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer\u2019s Cresemba Wins NMPA Pediatric Approval for Invasive Fungal Infections"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56882"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56882\/revisions"}],"predecessor-version":[{"id":56884,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56882\/revisions\/56884"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56883"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}